Marianna Chmiel

Marianna Chmiel

Auto-generated profile, based on publicly available information

Marianna Chmiel

4th Military Clinical Hospital with Polyclinic in Wrocław, Wrocław, Poland

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2025 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
JSJulia Szczotka
Julia Szczotka
GSGabriela Szpila
Gabriela Szpila
RFRemigiusz Flakus
Remigiusz Flakus
ŻKŻaneta Kania
Żaneta Kania
GKGabriela Kapłon
Gabriela Kapłon
KGKarolina Glajcar
Karolina Glajcar
Alzheimer’s disease (AD) is the most prevalent neurodegenerative disorder worldwide and constitutes a significant public health concern due to its rising incidence and the absence of curative therapies. This review synthesizes recent pharmacological progress in the treatment of AD, with particular emphasis on emerging therapeutic strategies and investigational drug classes. The analysis draws on clinical trial data, regulatory documents, and peer-reviewed literature published between 2017 and 2025, identified through major scientific databases including PubMed, Scopus, and ClinicalTrials.gov. The most promising advances are associated with monoclonal antibodies directed against amyloid-beta pathology, such as aducanumab, lecanemab, and donanemab, which show potential to modify disease progression but also raise concerns related to efficacy, safety, and regulatory approval. Additional innovative approaches, including tau-targeted therapies, gene editing technologies such as CRISPR-Cas9, and RNA interference (RNAi), present new therapeutic opportunities, though they remain limited by challenges such as amyloid-related imaging abnormalities (ARIA), restricted delivery across the blood–brain barrier, and uncertainties regarding long-term clinical outcomes. While currently available pharmacological options are insufficient to halt or reverse AD, recent advancements, particularly in antibody-based therapies, represent an important step toward a new therapeutic era. Nevertheless, cautious interpretation of preliminary findings and rigorous clinical validation remain essential before these strategies can be translated into widespread clinical practice.

30 September 2025 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
DGDominika Gieroba
Dominika Gieroba
AKAnna Kamieniak
Anna Kamieniak
WPWeronika Perczyńska
Weronika Perczyńska
GKGabriela Kapłon
Gabriela Kapłon
JSJulia Szczotka
Julia Szczotka
KGKarolina Glajcar
Karolina Glajcar
Research objectives: Irritable bowel syndrome (IBS) is a functional disorder of the gastrointestinal tract with a complex pathogenesis in which the brain-gut axis is disrupted. Due to the multifactorial basis of the disorder, it is very important to combine pharmacological and psychological treatment with dietary treatment to alleviate patients' symptoms. The purpose of this dissertation was to present the effectiveness of pharmacological, dietary, psychological and novel treatments currently at research level in patients with irritable bowel syndrome. Method: In order to evaluate the effectiveness of various therapies in IBS, a systematic review was conducted. It covers articles from years 2020 - 2024, that were published in PubMed, MDPI, and Sage Journals databases. Key Findings: The treatment of irritable bowel syndrome requires a combination of different therapies to achieve an effective therapeutic effect. There is no specific form of treatment to cure IBS. Conclusions: Currently it is only possible to alleviate the discomfort and improve the quality of life by combining the various methods available. The method that seems to be the most effective is a combination of pharmacological, dietary and psychological treatment. Pharmacological therapy makes it possible to alleviate pain, constipation or diarrhea. The introduction of the FODMAP diet eliminates factors that adversely affect the intestinal microbiota, and psychotherapy, combined with pharmacological treatment of depression and anxiety, alters thinking and synthesizes hormones that affect the gut-brain axis. Alternative treatments are currently being researched, but it will take time and further research before these methods can be incorporated into standard therapy.

30 September 2025 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
MCMarianna Chmiel
Marianna Chmiel
ATArtur Tumiński
Artur Tumiński
GKGabriela Kapłon
Gabriela Kapłon
WPWeronika Perczyńska
Weronika Perczyńska
JSJulia Szczotka
Julia Szczotka
DGDominika Gieroba
Dominika Gieroba
Introduction and objective: Haemophagocytic lymphohistiocytosis (HLH) is a rare, life-threatening hyperinflammatory syndrome that may follow viral infections. We present a case of a 12-month-old boy who developed disseminated intravascular coagulation (DIC) and fulfilled HLH diagnostic criteria following influenza A virus infection. Extensive diagnostics excluded a genetic cause. Treatment based on the HLH-2018 protocol led to full recovery. This case emphasizes the importance of considering HLH in infants with severe systemic inflammation and coagulopathy, even in the absence of EBV infection. Early recognition and appropriate therapy are essential to improve outcomes. Results. This case report describes a 12-month-old boy with haemophagocytic lymphohistiocytosis (HLH) and disseminated intravascular coagulation (DIC) following influenza A infection. Despite negative genetic testing, the patient met HLH diagnostic criteria. Treatment per HLH-2018 protocol was successful. The case underscores the importance of early recognition of HLH in viral infections beyond Epstein-Barr virus.

30 September 2025 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
GKGabriela Kapłon
Gabriela Kapłon
WPWeronika Perczyńska
Weronika Perczyńska
JSJulia Szczotka
Julia Szczotka
GSGabriela Szpila
Gabriela Szpila
RFRemigiusz Flakus
Remigiusz Flakus
MCMarianna Chmiel
Marianna Chmiel
Background: Hashimoto’s thyroiditis is one of the most common autoimmune diseases, with a noticeable increase in incidence observed in recent years. Despite its high prevalence, current treatment options remain limited and primarily focus on managing the consequences rather than addressing the underlying causes of the condition. Metformin, although primarily prescribed for diabetes, has demonstrated promising anti-inflammatory and immunoregulatory properties in several autoimmune disease models. Aim: This review aims to evaluate the potential role of metformin in the management of Hashimoto’s thyroiditis, with a particular focus on its effects on immune regulation and thyroid function. Methods: An electronic literature search was performed using PubMed, Cochrane Library, ScienceDirect and Evidence‑Based Medicine Reviews. Search terms included ‘Metformin’, ‘Hashimoto disease’, ‘Thyroiditis’, ‘Thyroid’, ‘autoimmune disease’ as keywords. Only articles in English were considered. Conclusions: Preliminary data suggest that metformin, through its anti-inflammatory properties and modulation of AMPK/mTOR pathways, may influence immune responses in Hashimoto’s thyroiditis. Despite promising preclinical findings, further clinical trials involving human participants are required to evaluate its therapeutic efficacy and safety in this context.

6 March 2025 in Journal of Education, Health and Sport
Verified
Journal Article
Open access
PDF file
APAnna Podraza
Anna Podraza
KSKarolina Sacher
Karolina Sacher
OMOliwia Maciaszek
Oliwia Maciaszek
MTMariola Turemka
Mariola Turemka
MCMarianna Chmiel
Marianna Chmiel
Introduction and Objective: Acne is one of the most common dermatological diseases. It mainly affects young people, but is more and more common in older people. There are reports on the effectiveness of treatment with botulinum toxin in acne vulgaris, acne rosacea and in the treatment of acne scars. The article takes into account research examining the effect of BTX as a method of treating acne. The results indicate that the use of BTX therapy as the method of treating acne may be effective. However, further research on its use in this therapy is necessary. Methods: The article is a review on the effect of botulinum toxin on acne vulgaris, rosacea and on the treatment of scars. works from 1999-2024 were used to create the article. On their basis, conclusions were drawn. Results: The results obtained based on the research review indicate a great potential for the use of botulinum toxin in the treatment of acne and acne scars. However, more research is needed on a larger population of patients to clearly assess the effectiveness of botulinum toxin therapy and adjust the appropriate doses of the preparation.

6 March 2025 in Journal of Education, Health and Sport
Verified
Journal Article
Open access
PDF file
ACAleksandra Cygnarowicz
Aleksandra Cygnarowicz
OMOliwia Maciaszek
Oliwia Maciaszek
MBMikołaj Biskupski
Mikołaj Biskupski
MTMariola Turemka
Mariola Turemka
MCMarianna Chmiel
Marianna Chmiel
KZKrystyna Zabojska
Krystyna Zabojska
Introduction and Objective Takayasu's arteritis (TAK) is a chronic autoimmune vasculitis that primarily impacts the aorta and its major branches. The standard treatment has been glucocorticoids; however, their prolonged usage can cause severe side effects, and many patients fail to maintain sustained remission. This review aims to assess the recent advances in utilizing biological drugs for treating TAK, with a focus on their efficacy and safety profiles. Methods To conduct this review, we analyzed clinical trials, retrospective studies, and case reports. The databases searched included PubMed, MEDLINE, and Scopus utilizing keywords like "Takayasu arteritis," "biological treatment," and specific medication names. Brief Description of the Current State of Knowledge Several biological therapies targeting key inflammatory pathways implicated in TAK have demonstrated promise. These include IL-6 inhibitors (tocilizumab), TNF-alpha inhibitors (infliximab, etanercept), and JAK inhibitors (tofacitinib). Clinical research and case reports indicate these therapies can decrease disease activity, facilitate glucocorticoid tapering, and enhance quality of life in patients who do not sufficiently respond to standard treatment. However, concerns remain about long-term safety, including heightened infection risk and paradoxical inflammatory reactions. Summary Biological medications represent a major step forward in TAK treatment, providing hope for individuals unresponsive to conventional approaches. However, additional large-scale, randomized controlled trials are needed to establish their long-term efficacy and safety of the treatment.